Avanos Medical (NYSE:AVNS) Updates FY24 Earnings Guidance

Avanos Medical (NYSE:AVNS) updated its FY24 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $1.30-1.45 for the period, compared to the consensus estimate of $1.38. The company issued revenue guidance of $685-705 million, compared to the consensus revenue estimate of $695.40 million.

Avanos Medical Trading Up 0.3 %

NYSE:AVNS opened at $22.96 on Wednesday. Avanos Medical has a 12 month low of $17.24 and a 12 month high of $24.54. The company has a current ratio of 2.28, a quick ratio of 1.47 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $20.38 and a 200-day moving average price of $19.68. The stock has a market cap of $1.05 billion, a price-to-earnings ratio of -17.26 and a beta of 0.94.

Analyst Ratings Changes

A number of research firms have commented on AVNS. JMP Securities reissued a market perform rating on shares of Avanos Medical in a report on Tuesday, May 7th. StockNews.com raised Avanos Medical from a hold rating to a buy rating in a research report on Saturday, May 11th.

About Avanos Medical

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.